Skip to main content
. 2023 Apr 16;12(11):12325–12335. doi: 10.1002/cam4.5931

FIGURE 4.

FIGURE 4

Recurrence‐free survival time after conversion therapy with curative or other therapies. The red, blue, and green line indicates the curative therapy, Atez/Bev discontinuation, and TACE group, respectively. Atez/Bev, atezolizumab plus bevacizumab; TACE, transarterial chemoembolization.